- Citations, last 5 years
- 14
- Works, last 5 years
- 2
- h-index
- 34
- Scientists listed
- 0
- Grants since 2016
- 19
Grants received
2023–2024 · contract · N01
Task C2: Analytical Method, Process Development and Manufacturing for Therapeutics
Isabel Scholz · Nanotherapeutics (United States) · funded by National Institutes of Health
2023–2024 · contract · N01
Task C2: Analytical Method, Process Development and Manufacturing for Therapeutics
Isabel Scholz · Nanotherapeutics (United States) · funded by National Institutes of Health
2022–2024 · research · R41
Overcoming Breast Cancer Therapeutic Resistance by Multifunctional RNA Nanoparticles
Xiaoting Zhang · Nanotherapeutics (United States) · funded by National Institutes of Health
2022–2024 · research · R41
Overcoming Breast Cancer Therapeutic Resistance by Multifunctional RNA Nanoparticles
Xiaoting Zhang · Nanotherapeutics (United States) · funded by National Institutes of Health
2022–2023 · research · R41
Nanoimmunotherapy for chronic immune-mediated diseases
David A Horwitz · Nanotherapeutics (United States) · funded by National Institutes of Health
2019–2022 · contract · N01
Advanced Development of Medical Countermeasures for Infectious Diseases
Milan Tomic · Nanotherapeutics (United States) · funded by National Institutes of Health
2019–2024 · contract · N01
Advanced Development of Medical Countermeasures for Infectious Diseases
Milan Tomic · Nanotherapeutics (United States) · funded by National Institutes of Health
2019–2021 · contract · N01
Advanced Development of Medical Countermeasures for Infectious Diseases
Milan Tomic · Nanotherapeutics (United States) · funded by National Institutes of Health
2019–2021 · contract · N01
Advanced Development of Medical Countermeasures for Infectious Diseases
Milan Tomic · Nanotherapeutics (United States) · funded by National Institutes of Health
2019–2024 · contract · N01
Advanced Development of Medical Countermeasures for Infectious Diseases
Milan Tomic · Nanotherapeutics (United States) · funded by National Institutes of Health
2019–2022 · contract · N01
Advanced Development of Medical Countermeasures for Infectious Diseases
Milan Tomic · Nanotherapeutics (United States) · funded by National Institutes of Health
2017–2020 · contract · N01
TASK B1: STABILITY TESTING OF THERAPEUTICS FOR BOTULISM
Robert House · Nanotherapeutics (United States) · funded by National Institutes of Health
2017–2018 · contract · N01
TASK B1: STABILITY TESTING OF THERAPEUTICS FOR BOTULISM
Robert House · Nanotherapeutics (United States) · funded by National Institutes of Health
2016–2023 · cooperative agreement · U01
EMB-001: A novel combination therapy for the treatment of cocaine-use disorder
Bruce Mccarthy · Nanotherapeutics (United States) · funded by National Institutes of Health
2016–2020 · cooperative agreement · U01
EMB-001: A novel combination therapy for the treatment of cocaine-use disorder
Michael J. Detke · Nanotherapeutics (United States) · funded by National Institutes of Health
2016–2017 · contract · N01
PRECLINICAL SERVICES FOR BIOPHARMACEUTICAL PRODUCT DEVELOPMENT
Joann Brown · Nanotherapeutics (United States) · funded by National Institutes of Health
2016–2020 · cooperative agreement · U01
EMB-001: A novel combination therapy for the treatment of cocaine-use disorder
Michael J. Detke · Nanotherapeutics (United States) · funded by National Institutes of Health
2014–2022 · research · R42
Albumin Nanoparticles Incorporating Piceatannol (PANPs) for ALI/ARDS therapy
Prasad V. S. Kanteti · Nanotherapeutics (United States) · funded by National Institutes of Health
2014–2020 · research · R42
Albumin Nanoparticles Incorporating Piceatannol (PANPs) for ALI/ARDS therapy
Prasad V. S. Kanteti · Nanotherapeutics (United States) · funded by National Institutes of Health